

3Q 2022 Fact Sheet

Jeisys

Disclaimer

► it is suggested to use this material only as a reference, as it contains information and data that are subject to changes without prior notice due to uncertainties, changes in the organizational structure, redefinition of accounting policies, etc., and may cause the actual results to differ from those stated or implied in this material.

I. P/L (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Sales	11,484	7,867	14,276	14,202	47,829	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642		84,746
Cost of Goods sold	3,569	2,831	3,149	4,541	14,090	4,712	5,913	6,026	7,998	24,649	7,638	10,056	9,160		26,854
Ratio(%)	31%	36%	22%	32%	29%	27%	31%	30%	33%	30%	30%	33%	32%		32%
Gross profit	7,915	5,036	11,127	9,661	33,739	12,546	13,326	14,378	16,397	56,647	17,696	20,715	19,482		57,893
Ratio(%)	69%	64%	78%	68%	71%	73%	69%	70%	67%	70%	70%	67%	68%		68%
SG&A	4,966	5,950	4,357	7,435	22,709	7,613	7,460	8,184	9,784	33,042	9,147	11,753	11,766		32,666
Operating profit	2,949	-914	6,770	2,226	11,030	4,933	5,865	6,194	6,613	23,604	8,549	8,962	7,716		25,227
Ratio(%)	26%	-12%	47%	16%	23%	29%	30%	30%	27%	29%	34%	29%	27%		30%
Net profit before income tax	2,988	-2,767	6,525	1,468	8,215	-5,657	5,747	6,391	6,613	13,093	8,399	9,366	9,111		26,876
Net profit	2,434	-2,622	6,250	1,481	7,543	-6,303	5,634	6,135	8,026	13,493	6,512	7,360	7,182		21,054
Ratio(%)	21%	-33%	44%	10%	16%	-37%	29%	30%	33%	17%	26%	24%	25%		25%
EBITDA	3,404	-236	7,312	2,880	13,254	5,507	6,413	6,859	7,245	26,024	9,257	9,704	8,333		27,295
Ratio(%)	30%	-3%	51%	20%	28%	32%	33%	34%	30%	32%	37%	32%	29%		32%

Note1) 2021 1Q _ Other losses (Merger cost KRW 10,569million)

II. Sales by product portfolio (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
HIFU	2,036	2,918	2,207	3,036	10,198	3,304	3,466	3,601	2,645	13,015	3,628	3,062	5,945		12,635
RF	2,584	464	1,375	2,605	7,028	3,974	2,994	3,837	5,881	16,686	7,058	9,355	5,923		22,336
IPL	861	604	599	1,106	3,170	514	661	946	2,378	4,499	1,234	2,010	1,340		4,584
LASER	1,336	381	591	416	2,724	1,591	2,007	2,295	1,797	7,690	2,503	2,596	3,418		8,516
Consumables	4,011	2,738	8,602	6,557	21,907	7,260	9,413	9,573	11,069	37,315	10,237	13,120	10,740		34,097
Others	655	762	902	482	2,801	615	699	153	625	2,091	674	628	1,277		2,578
Total	11,484	7,867	14,276	14,202	47,829	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642		84,746

III. Sales by Regional (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
Domestic	2,208	1,792	2,644	2,567	9,211	2,459	2,848	3,093	3,743	12,144	3,433	3,894	4,882		12,209
Overseas	9,276	6,075	11,632	11,635	38,617	14,798	16,391	17,311	20,652	69,152	21,901	26,876	23,761		72,538
Total	11,484	7,867	14,276	14,202	47,829	17,258	19,239	20,404	24,395	81,296	25,334	30,770	28,642		84,746

IV. Major Device Sales

Total company (Unit : EA)	2020					2021					2022				
	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative	1Q	2Q	3Q	4Q	Cumulative
LinearFirm / LinearZ	120	175	126	146	567	164	196	212	171	743	238	186	312		736
Cumulative Sales	988	1,163	1,289	1,435	-	1,599	1,795	2,007	2,178	-	2,416	2,602	2,914		-
POTENZA	100	13	70	91	274	175	99	108	192	574	300	410	197		907
Cumulative Sales	287	300	370	461	-	636	735	843	1,035	-	1,335	1,745	1,942		-

V. B/S (K-IFRS)

Consolidated based on K-IFRS (Unit : KRW million)	2020					2021					2022				
	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31	1Q	2Q	3Q	4Q	12/31
Current assets	21,816	20,097	26,984	28,264	28,264	41,060	39,180	46,012	54,173	54,173	61,487	67,776	69,877		
Cash and cash equivalents	7,759	9,533	17,047	17,591	17,591	19,582	23,263	28,668	34,291	34,291	36,394	32,274	33,627		
Short-term trade Receivable	5,145	3,041	2,562	3,338	3,338	5,945	5,144	5,183	6,872	6,872	8,198	11,000	9,433		
Inventories	6,993	5,888	5,653	5,766	5,766	6,190	8,171	9,679	10,578	10,578	13,234	18,329	20,423		
Non-current assets	8,797	10,368	10,153	10,903	10,903	10,829	11,316	12,468	19,886	19,886	23,692	27,686	35,460		
Total assets	30,613	30,465	37,136	39,167	39,167	51,889	50,496	58,481	74,059	74,059	85,178	95,462	105,337		
Current liabilities	23,901	10,429	10,668	12,918	12,918	12,957	14,799	14,548	24,027	24,027	24,757	29,097	23,923		
Non-current liabilities	13,217	16,669	11,157	9,290	9,290	9,936	8,678	8,569	2,379	2,379	4,040	3,995	10,485		
Total liabilities	37,118	27,098	21,825	22,208	22,208	22,893	23,477	23,117	26,405	26,405	28,797	33,092	34,409		
Issued capital	2,048	2,767	3,043	3,043	3,043	7,063	7,063	7,130	7,130	7,130	7,130	7,130	7,130		
Total equity	-6,505	3,367	15,312	16,959	16,959	28,996	27,020	35,364	47,654	47,654	56,381	62,370	70,928		

Jeisys Medical Inc.

Hang-In Lee (IR Team leader) / Mail : hilee@jeisys.com